EXPRESSION AND IMMUNOASSAY ASSESSMENT OF IMMUNOMODULATORY PanDR AND SARS-CoV-2 RECEPTOR-BINDING DOMAIN ANTIGEN IN BACTERIA HOST CELL.

Authors

Rukayat Olajumoke Onilegbale, Gbemisola Morounke Saibu, Habeeb Adebodun Bankole, Rebecca Oziohu Omosimua, Muinah Adenike Fowora, Ayorinde Babatunde James

Published in

Protein expression and purification. Pages 106982. Jul 25, 2026. Epub Jul 25, 2026.

Abstract

The gap in technical capacity and inadequate infrastructure for biomanufacturing limits progress in vaccine development and biomanufacturing in low- and middle-income countries (LMICs). Peptide subunit antigens offer a promising solution to producing cost-effective, safe and protective vaccines for SARS-CoV-2 and other emerging viral diseases. The receptor-binding domain (RBD) of the SARS-CoV-2 spike protein, which mediates viral entry through interaction with the human angiotensin-converting enzyme 2 (ACE2) receptor, represents a suitable model antigen for building and strengthening local capacity. The aim of this study is to express and validate a recombinant SARS-CoV-2 RBD protein as a vaccine candidate using bacterial expression systems. In this study the RBD sequence is linked to PanDR epitope sequence, an immunostimulant' then codon optimized for bacterial expression. The physicochemical parameter of the protein sequence was assessed using in-silico tools to assess its suitability. The sequence was synthesized chemically, and cloned into a pMAL-c6T expression vector, then transformed into Escherichia coli BL21-DE3 cells. The protein was expressed by IPTG induction for three hours in Luria-Bertani nutrient media and then purified using affinity chromatography. The recombinant protein was successfully expressed in a bacterial expression system as revealed by a distinct band at the expected molecular weight of approximately 74.5 kDa, on SDS-PAGE corresponding to the MBP-RBD fusion protein. Western blot analysis further confirmed the identity of the protein through specific recognition by anti-MBP antibody. The results show that the modified receptor binding domain protein of SARS-CoV-2 was successfully synthesized, cloned, expressed and validated for further immunological evaluation.

PMID:
42501923
Bibliographic data and abstract were imported from PubMed on 26 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.